FOSTER CITY, CA--(Marketwire - June 02, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will present a corporate overview and business update at the Jefferies 2011 Global Healthcare Conference on Thursday, June 9, 2011 at 12:30 pm ET in New York City.
To access the live audio webcasts of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, China-centric specialty pharmaceutical company with a substantial business and a product portfolio of novel therapies for cancer, infectious diseases and cardiovascular, urology and central nervous system disorders, and respiratory conditions. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries for the treatment of hepatitis B (HBV), as a vaccine adjuvant, for the treatment of hepatitis C (HCV), and certain cancers. SciClone markets nearly 20 products in China besides ZADAXIN, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace, an ACE inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US), and Aggrastat®, a recently-launched intervention[al] cardiology product. The Company also has a pipeline of China-focused assets awaiting regulatory approval in that country. On the global development side, SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.
Ambien, Depakine and Stilnox are registered trademarks of Sanofi-Aventis.
Aggrastat is a registered trademark of Merck & Co., Inc.
